A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
Cancer|Oncology|Tumors|Advanced Malignancy|Advanced Solid Tumors|Oncology Patients
DRUG: AMG 208
To determine the maximum tolerated dose (MTD) of AMG 208, if possible, 3.5 years|To evaluate for clinical responses associated with AMG 208 treatment in subjects (Dose Expansion) with advanced solid malignancies according to RECIST criteria, 3.5 years|To characterize the pharmacokinetic (PK) exposure of AMG 208 when administered orally to subjects with advanced solid malignancies, 3.5 years|To evaluate the safety and tolerability of AMG 208 in subjects with advanced solid malignancies, 3.5 years
To evaluate for a decrease in tumor cell proliferation associated with AMG 208 treatment in subjects with advanced solid malignancies according to FLT-PET scanning, 3.5 years|To assess tumor volume changes after AMG 208 treatment by computed tomography (CT) or magnetic resonance imaging (MRI), 3.5 years|To assess skin specimens for potential biomarkers, 3.5 years|To determine whether c-Met expression, mutation, or amplification in tumor specimens correlates with a response to AMG 208, 3.5 years
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.